The Iranian National Formulary (INF) has more than 2,300 molecules registered at the Iran's Ministry of Health, including various strengths and dosage forms. The standards regarding pharmaceutical products in Iran are determined and modified by the Pharmacopeia Council.
Iran has adopted a full generic-based National Drug Policy (NDP), with local production of essential drugs and vaccines as one of the main goals.[1]
| Molecule | Sales for the first 6 month of 2010 (in Iranian Rials) | ||
|---|---|---|---|
| 1 | INTERFERON | 423,996,630,000 | |
| 2 | CEFIXIME | 397,896,015,000 | |
| 3 | 323,624,414,264 | ||
| 4 | CO-AMOXICLAV | 231,047,948,600 | |
| 5 | ACETAMINOPHEN | 210,953,849,492 | |
| 6 | ALBUMIN | 210,632,806,000 | |
| 7 | DOCETAXEL | 182,924,555,600 | |
| 8 | IMIPENEM+CILASTATAIN | 181,099,640,000 | |
| 9 | CLOPIDOGREL | 169,915,498,015 | |
| 10 | IMMUNE GLOBULIN | 160,575,717,000 | |
| 11 | ENOXAPARIN | 145,486,724,600 | |
| 12 | CEFALEXIN | 142,499,418,000 | |
| 13 | DEXTROSE | 141,272,434,000 | |
| 14 | ATORVASTATIN | 132,514,275,600 | |
| 15 | PANTOPRAZOL | 130,971,241,400 | |
| 16 | SALMETEROL | 127,780,028,000 | |
| 17 | SODIUM CHLORIDE | 126,043,613,100 | |
| 18 | IBUPROFEN | 125,621,562,500 | |
| 19 | RITUXIMAB | 118,690,006,000 | |
| 20 | ERYTHROPOIETIN | 110,191,720,000 |